FloraWorks

With another year behind us with no federal legalization of marijuana and no approval of the SAFE Banking Act, the industry’s biggest problem remains the lack of access to capital. What will happen in 2024? Are we any closer to either of these reforms? At first glance it...

Alleh Lindquist, CEO of FloraWorks, was a panelist on “Inside Out: The Synergy Between Cannabis and Wellness” at Benzinga’s Cannabis Capital Conference. Lindquist talked about the importance of prioritizing proof of efficacy and clinical stage studies to better understand how...

FloraWorks Holdings, a cannabinoid therapeutics firm, has disclosed groundbreaking results from the first-ever double-blind, randomized, placebo-controlled trial for its prime offering, TruCBN, Benzinga Cannabis has learned exclusively. TruCBN is a pure form of Cannabinol (CBN), one among the...

FloraWorks, a cannabinoid therapeutics company specializing in rare and novel cannabinoids, has successfully completed a $2.25 million Series-A financing round. Leading this significant investment was life sciences venture capital firm, Bonaventure Equity LLC. Other participants in the round...